

Mantle Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/M30B078F31C9EN.html>

Date: May 2024

Pages: 138

Price: US\$ 6,499.00 (Single User License)

ID: M30B078F31C9EN

Abstracts

The 7 major mantle cell lymphoma markets reached a value of US\$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.9 Billion by 2034, exhibiting a growth rate (CAGR) of 5.76% during 2024-2034.

The mantle cell lymphoma market has been comprehensively analyzed in IMARC's new report titled "Mantle Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mantle cell lymphoma (MCL) refers to an aggressive, rare kind of B-cell non-Hodgkin lymphoma that arises in the white blood cells of the lymph nodes, bone marrow, and other tissues. Depending on the causative factor and extent of the disease, MCL is categorized into nodal and leukemic non-nodal mantle cell lymphoma. The most common symptoms of this ailment include fevers, lower back pain, night sweats, loss of appetite and weight, unexplained itching, swollen lymph nodes in the neck, armpits, or groin, nausea, vomiting, fatigue, heartburn, etc. Additionally, patients may also experience bloating, diarrhea, or abdominal pain if the lymphoma affects the gastrointestinal region. The diagnosis usually requires a combination of medical history, blood tests, and laboratory studies. Various other investigations, such as positron emission tomography (PET) scan, computed tomography (CT) scan, polymerase chain reaction, etc., are also utilized to confirm the prognosis. Besides this, the healthcare professional may perform an excisional biopsy of the lymph node to validate the disease staging in the patient.

The increasing cases of genetic disorders due to gene alteration and overexpression, resulting in abnormal proliferation of cancer cells, are primarily driving the mantle cell lymphoma market. Apart from this, the expanding geriatric population, who are more susceptible to certain infections owing to weakened immune systems, is also bolstering

the market growth. Additionally, the widespread adoption of immune-based therapies, which strengthen the patient's defense system to destroy lymphoma cells and retard their development, is creating a positive outlook for the market. Besides this, the inflating usage of Fluorescence In-situ Hybridization (FISH) for diagnosing the ailment on account of its several benefits, such as a better understanding of chromosomal abnormalities and genetic mutations with high specificity and sensitivity, is also augmenting the market growth. Moreover, the emerging popularity of BTK inhibitors, including ibrutinib and acalabrutinib, for targeting specific proteins or genes involved in the development and spread of cancer cells is further acting as another significant growth-inducing factor. In addition to this, the escalating demand for radioimmunotherapy to treat MCL, since it offers more personalized therapy against unhealthy cells and limits radiation exposure to normal tissue, is expected to drive the mantle cell lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the mantle cell lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mantle cell lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mantle cell lymphoma market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the mantle cell lymphoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the mantle cell lymphoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current mantle cell lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the mantle cell lymphoma market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the mantle cell lymphoma market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the mantle cell lymphoma market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of mantle cell lymphoma across the seven major markets?

What is the number of prevalent cases (2018-2034) of mantle cell lymphoma by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of mantle cell lymphoma by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with mantle cell lymphoma across the seven major markets?

What is the size of the mantle cell lymphoma patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of mantle cell lymphoma?

What will be the growth rate of patients across the seven major markets?

Mantle Cell Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for mantle cell lymphoma drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mantle cell lymphoma market?

What are the key regulatory events related to the mantle cell lymphoma market?

What is the structure of clinical trial landscape by status related to the mantle cell lymphoma market?

What is the structure of clinical trial landscape by phase related to the mantle cell lymphoma market?

What is the structure of clinical trial landscape by route of administration related to the mantle cell lymphoma market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 MANTLE CELL LYMPHOMA - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034?)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034?)
- 4.5 Competitive Intelligence

5 MANTLE CELL LYMPHOMA - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 MANTLE CELL LYMPHOMA - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034?)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034?)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034?)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034?)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034?)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034?)
 - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034?)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034?)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 MANTLE CELL LYMPHOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 MANTLE CELL LYMPHOMA - UNMET NEEDS

10 MANTLE CELL LYMPHOMA - KEY ENDPOINTS OF TREATMENT

11 MANTLE CELL LYMPHOMA - MARKETED PRODUCTS

- 11.1 List of Mantle Cell Lymphoma Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Revlimid (Lenalidomide) - Celgene
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Tecartus (Brexucabtagene autoleucel) - Kite Pharma
 - 11.1.2.1 Drug Overview

- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Brukinsa (Zanubrutinib) - BeiGene
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Imbruvica (Ibrutinib) - Janssen/Pharmacyclics
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Calquence (Acalabrutinib) - Acerta Pharma/AstraZeneca
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 MANTLE CELL LYMPHOMA - PIPELINE DRUGS

- 12.1 List of Mantle Cell Lymphoma Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Abemaciclib - Eli Lilly and Company
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status
 - 12.1.2 Venetoclax - AbbVie/Genentech
 - 12.1.2.1 Drug Overview
 - 12.1.2.2 Mechanism of Action
 - 12.1.2.3 Clinical Trial Results
 - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 Elimusertib - Bayer
 - 12.1.3.1 Drug Overview
 - 12.1.3.2 Mechanism of Action
 - 12.1.3.3 Clinical Trial Results
 - 12.1.3.4 Safety and Efficacy
 - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

13. MANTLE CELL LYMPHOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. MANTLE CELL LYMPHOMA – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 MANTLE CELL LYMPHOMA - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Mantle Cell Lymphoma - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034?)
 - 15.2.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034?)
- 15.3 Market Scenario - United States
 - 15.3.1 Mantle Cell Lymphoma - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034?)
 - 15.3.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.3.3 Mantle Cell Lymphoma - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany

- 15.4.1 Mantle Cell Lymphoma - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034?)
- 15.4.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034?)
- 15.4.3 Mantle Cell Lymphoma - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Mantle Cell Lymphoma - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034?)
 - 15.5.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.5.3 Mantle Cell Lymphoma - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Mantle Cell Lymphoma - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034?)
 - 15.6.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.6.3 Mantle Cell Lymphoma - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Mantle Cell Lymphoma - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034?)
 - 15.7.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.7.3 Mantle Cell Lymphoma - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Mantle Cell Lymphoma - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034?)
 - 15.8.2 Mantle Cell Lymphoma - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034?)
 - 15.8.3 Mantle Cell Lymphoma - Access and Reimbursement Overview

15.9 Market Scenario - Japan

15.9.1 Mantle Cell Lymphoma - Market Size

15.9.1.1 Market Size (2018-2023)

15.9.1.2 Market Forecast (2024-2034?)

15.9.2 Mantle Cell Lymphoma - Market Size by Therapies

15.9.2.1 Market Size by Therapies (2018-2023)

15.9.2.2 Market Forecast by Therapies (2024-2034?)

15.9.3 Mantle Cell Lymphoma - Access and Reimbursement Overview

16 MANTLE CELL LYMPHOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 MANTLE CELL LYMPHOMA MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 MANTLE CELL LYMPHOMA MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Mantle Cell Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/M30B078F31C9EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M30B078F31C9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

